DS
CLYM

David Shaw’s Climb Bio CLYM Stock Holding History

David Shaw’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$376K Buy
+28,800
New +$297K ﹤0.01% 4320
2021
Q4 		– Sell
-14,912
Closed -$268K – 5767
2021
Q3 		$268K Buy
+14,912
New +$308K ﹤0.01% 4423

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

David Shaw's CLYM Position: Q2 2026 in Review

David Shaw opened a new position in Climb Bio (CLYM) in Q2 2026: 28,800 shares worth $376K. The stake represents ﹤0.01% of the portfolio and ranks #4320 among its holdings. This is a return to the name: David Shaw previously reported a position in CLYM as recently as Q3 2021.

David Shaw first reported a position in CLYM in Q3 2021 and has held it in 2 quarters since. 108 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • David Shaw held 28,800 shares of Climb Bio worth $376K as of Q2 2026.
  • Climb Bio was a new David Shaw position in Q2 2026.
  • Climb Bio made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #4320 holding.
  • David Shaw first reported a position in Climb Bio in Q3 2021 and has held it in 2 quarters since.
  • 108 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.